Talk:SoRI-20041

"antagonist-like", adjunct for releaser, given to inhibitor functionality simultaneously.
This compound appears as though it may introduce the same measure of DRI (cocaine) subjective intensity to that of a DRA (amphetamine), across the broad spectrum of release and duration as I speculate at this post offsite.

My premise is that what this RC does is allow for reuptake of dopamine to be inhibited at one and the same transporter, at the same time, that dopamine is released from by manner of binding when altered to allow a phosphorylated cascade out of that one and the same particular transporter. Which DRIs/DRAs previously did not, due to mutual exclusion of effect at the same individual transporter in any capacity. i.e. primacy for initial binding by either, etc. Nagelfar (talk) 06:43, 29 January 2012 (UTC)

Other MAT allosteric modulators:
Tropanyl that acts of allosteric modulator at SERT, may well fall within the spectrum of analogous compounds. Nagelfar (talk) 23:02, 8 December 2015 (UTC)